Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Overview of attention for article published in BMC Neurology, July 2013

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,886 followers.

#PublicaSalutIB Adverse events during the titration phase of interferon-beta in remitting-relaps... http://t.co/qDaeZ9I4yG @sonespases #HUSE

Background: This study aimed to correlate body mass index or biomarkers with the frequency http://t.co/MKm9ITPIgz

#neurology Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclero... http://t.co/bK12iJx6oe

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.